// App-Quantinova.ai

S189 : UPDATED RESULTS FROM PHASE 3 ANDROMEDA STUDY OF PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN AMYLOIDOSIS TREATED WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE PLUS SUBCUTANEOUS DARATUMUMAB

Researchers

Presenter

  • Efstathios Kastritis

Principal Investigators

  • Giovanni Palladini

  • Monique Minnema

  • Ashutosh Wechalekar

  • Arnaud Jaccard

  • Angela Dispenzieri

  • Hans Lee

  • Divaya Bhutani

  • Simon Gibbs

  • Peter Mollee

  • Christopher Venner

  • Jin Lu

  • Stefan Schnland

  • Moshe Gatt

  • Kenshi Suzuki

  • Kihyun Kim

  • Teresa Cibeira

  • Meral Beksac

  • Edward Libby

  • Jason Valent

  • Vania Hungria

  • Sandy Wong

  • Michael Rosenzweig

  • Naresh Bumma

  • Dominique Chauveau

  • NamPhuong Tran

  • Xiang Qin

  • Sandra Vasey

  • Brenda Tromp

  • Brendan Weiss

  • Jessica Vermeulen

  • Raymond Comenzo

  • Giampaolo Merlini

Medical Centers

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • Peking University Peoples Hospital & Peking University Institute of Hematology, Beijing, China

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Judy and Bernard Briskin Center for Multiple Myeloma Research,Duarte,United States

  • Division of General Pediatrics, Boston University School of Medicine/Boston Medical Center, Boston, MA

  • Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany

  • University Medical Center Utrecht, Utrecht, Netherlands

  • Princess Alexandra Hospital and University of Queensland, Brisbane, Australia

  • Monash University Eastern Health Clinical School, Melbourne, Australia

  • Development, Leiden, Netherlands

  • Japanese Red Cross Medical Center, Tokyo, Japan

  • Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia,Pavia,Italy

  • Development, LLC,Spring House,United States

  • Development,Los Angeles, CA,United States

  • Clinica Sao Peregrino, Sao Paulo, Brazil

  • CHU de Toulouse-Hospital Rnagueil, Toulouse, France

  • University of Washington, Seattle, WA, United States

  • Kings College London, London, United Kingdom

  • Janssen Research &amp

  • Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France

  • Samsung Medical Center, Sungkyunkwan University School of Medicine,Seoul,Korea, Democratic People's Republic Of

  • National and Kapodistrian University of Athens, Athens, Greece

  • Ankara University, Ankara, Turkey

  • Mayo Clinic, Rochester, United States

  • John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

  • University of California, San Francisco, San Francisco, California, United States

  • Columbia University, New York, New York, United States

  • Taussig Cancer Institute,Cleveland Clinic,Cleveland,Vereinigte Staaten

  • Hadassah-Hebrew-University-Medical-Cente, Jerusalem, Israel

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

Locations

  • Canada

  • China

  • United States

  • Spain

  • Germany

  • Netherlands

  • Australia

  • Japan

  • Italy

  • Brazil

  • France

  • United Kingdom

  • Republic of South Korea

  • Greece

  • Turkey

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • AL Amyloidosis

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT03201965

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved